Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

23.47
+1.135.06%
Post-market: 22.80-0.6700-2.85%19:42 EDT
Volume:587.99K
Turnover:13.40M
Market Cap:1.50B
PE:-8.53
High:23.48
Open:22.33
Low:22.13
Close:22.34
Loading ...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
10 Apr

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Benzinga
·
10 Apr

Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
07 Apr

Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept’s Potential in IgA Nephropathy

TIPRANKS
·
03 Apr

Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept

TIPRANKS
·
03 Apr

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

GlobeNewswire
·
03 Apr

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
12 Mar

Stock Track | Vera Therapeutics Soars 5.21% on Buy Rating and Price Target Increase from TD Cowen

Stock Track
·
06 Mar

Vera Therapeutics (VERA) Gets a Buy from TD Cowen

TIPRANKS
·
05 Mar

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Vera Therapeutics price target lowered to $71 from $77 at JPMorgan

TIPRANKS
·
04 Mar

Stock Track | Vera Therapeutics Soars 5.08% on Analyst Updates and Conference Participation

Stock Track
·
28 Feb

Vera Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
27 Feb

Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating

MT Newswires Live
·
27 Feb

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
27 Feb

Vera Therapeutics Inc : Raymond James Cuts Target Price to $73 From $76

THOMSON REUTERS
·
27 Feb

Vera Therapeutics Inc : Guggenheim Raises Target Price to $61 From $59

THOMSON REUTERS
·
27 Feb

Analysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)

TIPRANKS
·
27 Feb

Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook

TIPRANKS
·
27 Feb

Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M

MT Newswires Live
·
26 Feb